Every December the same thing happens: the furnace comes on, indoor humidity drops, and eyes that were fine all summer start feeling gritty and tired by mid-afternoon. Screen time makes it worse — people blink less when they stare at monitors — and contact-lens wearers feel it first.
The supplement advice for this has been remarkably consistent for about fifteen years: take fish oil. Optometrists suggest it, eye-health formulas are built around it, and the logic sounds good. It’s also a case where the research story has a twist worth understanding, because it illustrates exactly why we keep saying “one big trial beats ten small ones.”
Why Omega-3 Was Supposed to Help
Dry-eye discomfort often involves the tear film’s oily outer layer, produced by the meibomian glands along the eyelid margin. When that layer is thin or poor quality, tears evaporate too fast. Omega-3 fatty acids — EPA and DHA — are incorporated into the gland secretions and have well-documented effects on inflammatory signaling, so the hypothesis was that supplementing them would improve the oil layer and calm irritation of the eye surface.
Our omega-3 guide covers the basics of EPA versus DHA and why dose matters. For eye purposes, most products and trials used a combination, with total EPA + DHA ranging from around 1,000 to 3,000 mg per day.
The Early Trials: Encouraging But Thin
Through the 2000s and early 2010s, a series of small randomized trials reported that omega-3 supplementation improved dry-eye symptom scores, increased tear break-up time, and sometimes improved tear production measurements. Doses were typically 1,000–2,500 mg/day of combined EPA + DHA, with study lengths of one to three months.
A few things about these trials should have tempered enthusiasm more than they did:
- They were small — usually a few dozen participants.
- They were short — often 30 to 90 days.
- Several were funded by supplement manufacturers, which doesn’t make them wrong but does tend to correlate with positive results.
- Placebo matters a lot for a symptom-based condition — and some trials used oils (like certain vegetable oils) that may not be inert.
- Outcome measures varied widely, making the results hard to compare or pool.
Meta-analyses of these studies generally concluded that omega-3 showed benefit. That’s what drove the recommendation into standard practice.
The Big Trial: No Better Than Olive Oil
Several years ago, a large, government-funded, multicenter trial was published that was designed specifically to settle the question. It enrolled over 500 people with moderate to severe dry-eye symptoms, randomized them to either 3,000 mg/day of fish-oil-derived omega-3 (roughly 2,000 mg EPA and 1,000 mg DHA) or an olive-oil placebo, and followed them for a full year. Participants could continue their usual treatments — which matches real life, where people add supplements on top of eye drops rather than instead of them.
The result: both groups improved substantially, and the omega-3 group did not improve more than the placebo group. Not on the symptom questionnaire, not on tear break-up time, not on staining of the eye surface, not on tear production. Blood levels confirmed participants were actually taking the omega-3, so it wasn’t a compliance failure. An extension study that followed people for another year after stopping found no worsening in the people who had been on omega-3, which is consistent with the supplement not having been doing much.
A couple of caveats are fair. Olive oil is not perfectly inert — it contains compounds with some anti-inflammatory activity — so the comparison may have been slightly unfavorable to omega-3. And the participants had fairly significant symptoms and were already using other treatments; milder cases or people using nothing else might respond differently. But “maybe it works a little in a different population” is a long way from the confident recommendation that preceded the trial.
Where the Evidence Sits Now
When the large trial is pooled with the earlier work, the overall picture becomes “possible small benefit, low certainty.” Analyses that weight studies by size and quality lean toward no meaningful effect; analyses that treat all trials equally lean positive. It’s a useful lesson in how much pooled conclusions depend on which studies are in the pool.
The honest summary in late 2023:
- Omega-3 might modestly help some people with dry-eye symptoms, particularly those with meibomian gland involvement and a low dietary omega-3 intake.
- It is not a reliable fix, and the best evidence says the average benefit over placebo is small or zero.
- It is not a substitute for the things with stronger evidence: humidifiers, deliberate blinking breaks during screen work, warm compresses for the eyelid glands, and the lubricating drops or other approaches an eye-care professional recommends.
If You Want to Try It Anyway
Omega-3s have other reasonable uses — our omega-3 supplement page covers the cardiovascular and triglyceride evidence — so taking them isn’t a waste even if your eyes don’t notice. A sensible self-experiment looks like this:
- Dose: 1,000–2,000 mg/day of combined EPA + DHA (check the label for EPA and DHA amounts, not “fish oil” total — a 1,000 mg fish-oil softgel often contains only 300 mg of EPA + DHA).
- Form: Triglyceride-form fish oil or krill oil absorb well; re-esterified triglyceride forms used in some trials absorb somewhat better than ethyl ester forms.
- Timing: With a meal containing fat — absorption improves substantially and fishy burps decrease.
- Duration: Give it at least 3 months. Tissue omega-3 levels take that long to plateau.
- Evaluation: Note your symptoms before starting using something concrete — how many hours into the day before discomfort starts, how often you use drops. If nothing changes after 3 months, you have your answer.
Storage matters in winter too: keep softgels away from the radiator. Oxidized fish oil smells rancid and has lost some potency.
Safety
Omega-3 supplements at 1,000–3,000 mg/day are well tolerated. Points to know:
- Blood thinners and antiplatelet drugs: Omega-3s have a mild effect on platelet function. At usual doses this is rarely a problem, but tell your prescriber, and mention supplementation before any surgery — most surgeons ask you to pause fish oil for a week or two beforehand.
- Fish or shellfish allergy: Most people with fish allergy tolerate purified fish oil, but check with an allergist; algae-based DHA/EPA is an alternative.
- Digestive effects: Loose stools or reflux at higher doses. Splitting the dose and taking with food helps.
- Pregnancy and nursing: DHA is generally encouraged in pregnancy at modest doses (200–300 mg DHA/day is a common recommendation), but confirm your total intake with your provider.
- Quality: Choose brands with third-party testing for oxidation and heavy metals.
Bottom line
The small early trials said omega-3 helps dry eyes; the largest and best-designed trial said it does no better than olive oil. That makes omega-3 a low-risk, low-expectation option rather than the standard recommendation it’s often presented as. If you try it, use a real dose (1,000–2,000 mg EPA + DHA) with food for three months and judge it honestly — and don’t skip the humidifier, the blinking breaks, and a conversation with an eye-care professional if the dryness is persistent.
This article is educational and not medical advice. Consult a healthcare provider before starting any supplement, especially if you are pregnant, nursing, taking medication, or managing a health condition.